Investor directory

MaC Venture Capital

Founded in 2019, MaC Venture Capital is a venture capital firm based in Los Angeles, California. It specializes in early-stage investments across various technology sectors, including fintech, e-commerce, logistics, and more. The firm invests in companies that benefit from shifts in cultural trends and behaviors globally.
https://www.m-ventures.com
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=582962469
https://www.privateequityinternational.com/database/#/profile?id=16741

Ilja Aizenberg

Ken Aseme

Investor

Danny Brown

Partner

Alyson DeNardo

Partner

Adrian Fenty

Managing Partner

Past deals in Geneve

Prexton Therapeutics

Series B in 2017
Prexton Therapeutics SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It specializes in the development of innovative drugs for Parkinson's disease and other brain disorders. The company focuses on targeting metabotropic glutamate receptors, specifically mGluR4 and mGluR3, utilizing a novel scientific approach that integrates molecular, behavioral, and chemical technologies. Prexton Therapeutics aims to improve the quality of life for patients by offering alternatives to traditional dopaminergic treatments through its unique mGluR4 PAM series. This approach allows for quicker initiation of treatment, potentially leading to better medical outcomes for individuals suffering from these conditions.

Prexton Therapeutics

Series A in 2015
Prexton Therapeutics SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It specializes in the development of innovative drugs for Parkinson's disease and other brain disorders. The company focuses on targeting metabotropic glutamate receptors, specifically mGluR4 and mGluR3, utilizing a novel scientific approach that integrates molecular, behavioral, and chemical technologies. Prexton Therapeutics aims to improve the quality of life for patients by offering alternatives to traditional dopaminergic treatments through its unique mGluR4 PAM series. This approach allows for quicker initiation of treatment, potentially leading to better medical outcomes for individuals suffering from these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.